Revenue
No reported data
BiomX Inc. (PHGE)
Price—Loading quote
Net income
2019
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 · Dec 31 | 2019 · Jun 30 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | $21.3M | $24.7M | $16.7M | $16.2M | $22.7M | $19.4M | $13.5M | — | $9.1M |
| Operating expenses | — | — | — | $376,000 | — | — | — | $404,521 | $28,000 |
| Operating income | −$41.5M | −$44.5M | −$25.3M | −$27.2M | −$35.5M | −$30.3M | −$22.2M | −$404,521 | −$12.5M |
| EBITDAderived | — | — | −$24.5M | −$24.7M | −$32.9M | −$29.6M | −$21.9M | — | −$12.3M |
| Net income | −$36.2M | −$17.7M | −$26.2M | −$28.3M | −$36.2M | −$30.1M | −$20.6M | $347,407 | −$12.7M |
| Basic EPSper diluted share | $22.19 | $25.37 | $5.10 | $0.95 | $1.39 | $1.30 | $3.66 | -$0.15 | $7.62 |
| Diluted EPSper diluted share | $22.19 | $58.31 | $5.10 | $0.95 | $1.39 | $1.30 | $3.66 | -$0.15 | $7.62 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 17, 2026Form 4 | Yeganeh ReuvenDirector,TenPercentOwner | SellCommon Stock, $0.0001 par value per share · indirect | 530.0K | $5.00 | $2.65M | 0 |
| Mar 16, 2026Form 4 | Yeganeh ReuvenDirector,TenPercentOwner | SellCommon Stock, $0.0001 par value per share · indirect | 450.0K | $5.00 | $2.25M | 0 |
| Mar 16, 2026Form 4 | Yeganeh ReuvenDirector,TenPercentOwner | SellCommon Stock Purchase Warrants · derivative · indirect | 1.70M | $4.76 | $8.09M | 0 |
| Mar 16, 2026Form 4 | Yeganeh ReuvenDirector,TenPercentOwner | SellCommon Stock Purchase Warrants · derivative · indirect | 2.00M | $5.24 | $10.48M | 1.70M |
| Mar 16, 2026Form 4 | Yeganeh ReuvenDirector,TenPercentOwner | SellCommon Stock Purchase Warrants · derivative · indirect | 1.30M | $5.00 | $6.50M | 2.00M |